Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Epilepsy

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Related · question page
- Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only · ADHD symptoms
  Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only · Proportion of individuals withdrawing from treatment
  Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 0.65 [0.12, 3.59]
  1 study · 61 participants
  Low
Related · question page
- Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only · Seizure frequency (monthly, postintervention)
  Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 56 participants
  Low
Related · question page
- Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only · Proportion of people experiencing adverse drug events
  Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 1.4 [0.44, 4.42]
  1 study · 56 participants
  Low
Related · question page
- Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only · Seizure severity
  Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

50% or greater reduction in seizure frequency · people with ADHD and epilepsy

Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people achieving 50% or greater reduction in monthly… compared with risperidone and previous ASM only (low certainty).

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
RR 2.79 [0.84, 9.24]
1 study · 56 participants
Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

ADHD symptoms · people with ADHD and epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Adverse drug events · people with ADHD and epilepsy

Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people experiencing adverse drug events compared with risperidone and previous ASM only (low certainty).

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
RR 1.4 [0.44, 4.42]
1 study · 56 participants
Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Seizure frequency · people with ADHD and epilepsy

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy

Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of individuals withdrawing from treatment compared with risperidone and previous ASM only (low certainty).

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
RR 0.65 [0.12, 3.59]
1 study · 61 participants
Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Seizure severity · people with ADHD and epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found